Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Brooks, Alan ^a,b   Briët, Olivier J T ^a,b   Hardy, Diggory ^a,b   Steketee, Richard ^c   Smith, Thomas A ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ARTICLE; COMPUTER SIMULATION; DEATH; DRUG EFFICACY; DRUG HALF LIFE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MALARIA FALCIPARUM; PROTECTION; SCHOOL; VACCINATION; BIOLOGICAL MODEL; DISEASE TRANSMISSION; IMMUNOLOGY; MALARIA; MORTALITY; PREVENTIVE HEALTH SERVICE; PREVENTIVE MEDICINE; TIME;

COMPUTER SIMULATION; HUMANS; IMMUNIZATION PROGRAMS; MALARIA; MALARIA VACCINES; MODELS, IMMUNOLOGICAL; PREVENTIVE MEDICINE; TIME FACTORS;

EID: 84857840686     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032587     Document Type: Article

References (47)

1. Vekemans J, Leach A, Cohen J, (2009) Development of the RTS,S/AS malaria candidate vaccine. Vaccine 27 (Suppl 6): G67-G71.
2. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863-1875.
3. Ceesay SJ, Casals-Pascual C, Nwakanma DC, Walther M, Gomez-Escobar N, et al. (2010) Continued decline of malaria in The Gambia with implications for elimination. PLoS ONE 5: e12242.
4. O'Meara WP, Mangeni JN, Steketee R, Greenwood B, (2010) Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 10: 545-555.
5. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, et al. (2008) Malaria: progress, perils, and prospects for eradication. J Clin Invest 118: 1266-1276.
6. World Health Organization (2010) World Malaria Report.
7. Proietti C, Pettinato DD, Kanoi BN, Ntege E, Crisanti A, et al. (2011) Continuing intense malaria transmission in northern Uganda. Am J Trop Med Hyg 84: 830-837.
8. Aregawi MW, Ali AS, Al-mafazy AW, Molteni F, Katikiti S, et al. (2011) Reductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008. Malar J 10: 46.
9. Chizema-Kawesha E, Miller JM, Steketee RW, Mukonka VM, Mukuka C, et al. (2010) Scaling up malaria control in Zambia: progress and impact 2005-2008. Am J Trop Med Hyg 83: 480-488.
10. Kleinschmidt I, Schwabe C, Benavente L, Torrez M, Ridl FC, et al. (2009) Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg 80: 882-888.
11. Nyarango PM, Gebremeskel T, Mebrahtu G, Mufunda J, Abdulmumini U, et al. (2006) A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar J 5: 33.
12. Otten M, Aregawi M, Were W, Karema C, Medin A, et al. (2009) Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatment. Malar J 8: 14.
13. Roll Back Malaria Partnership (2010) Progress and Impact Series: Focus on Senegal.
14. Roll Back Malaria Partnership (2010) Progress and Impact Series: Focus on Zambia.
15. Steketee RW, Campbell CC, (2010) Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects. Malar J 9: 299.
16. Teklehaimanot HD, Teklehaimanot A, Kiszewski A, Rampao HS, Sachs JD, (2009) Malaria in Sao Tome and principe: on the brink of elimination after three years of effective antimalarial measures. Am J Trop Med Hyg 80: 133-140.
17. O'Brien C, Henrich PP, Passi N, Fidock DA, (2011) Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis 24: 570-577.
18. Ranson H, N'guessan R, Lines J, Moiroux N, Nkuni Z, et al. (2011) Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol 27: 91-98.
19. McNeil D, (2011) Global Fund Will Pause New Grants and Seek New Manager. New York Times.
20. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, et al. (2010) Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies. PLoS Med 7: e1000324.
21. Smith T, Maire N, Ross A, Penny M, Chitnis N, et al. (2008) Towards a comprehensive simulation model of malaria epidemiology and control. Parasitology 135: 1507-1516.
22. Maire N, Tediosi F, Ross A, Smith T, (2006) Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med Hyg 75: 111-118.
23. Penny MA, Maire N, Studer A, Schapira A, Smith TA, (2008) What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE 3: e3193.
24. Smith T, Ross A, Maire N, Chitnis N, Hardy D, et al. (2012) Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med 9 (1): e1001157.
25. UNICEF (2011) State of the World's Children.
26. Maire N, Shillcutt S, Walker DG, Tediosi F, Smith T, (2011) Cost effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the Expanded Program on Immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health 14: 1028-1038.
27. Malaria vaccine decision-making framework (2011) Available at: http://www.malvacdecision.net, Accessed: 19 September, 2011.
28. Milstien J, Cardenas V, Cheyne J, Brooks A, (2010) WHO policy development processes for a new vaccine: case study of malaria vaccines. Malar J 9: 182.
29. Smith T, Killeen GF, Maire N, Ross A, Molineaux L, et al. (2006) Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview. Am J Trop Med Hyg 75: 1-10.
30. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, et al. (2006) Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg 75: 11-18.
31. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, et al. (2006) A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas. Am J Trop Med Hyg 75: 19-31.
32. Smith T, Ross A, Maire N, Rogier C, Trape JF, et al. (2006) An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg 75: 56-62.
33. Ross A, Maire N, Molineaux L, Smith T, (2006) An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg 75: 63-73.
34. Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, et al. (2006) An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-saharan Africa. Am J Trop Med Hyg 75: 90-103.
35. Chitnis N, Schapira A, Smith T, Steketee R, (2010) Comparing the effectiveness of malaria vector-control interventions through a mathematical model. Am J Trop Med Hyg 83: 230-240.
36. Killeen GF, Chitnis N, Moore SJ, Okumu FO, (2011) Target product profile choices for intra-domiciliary malaria vector control pesticide products: repel or kill? Malar J 10: 207.
37. Maire N, Aponte JJ, Ross A, Thompson R, Alonso P, et al. (2006) Modeling a field trial of the RTS,S/AS02A malaria vaccine. Am J Trop Med Hyg 75: 104-110.
38. Owusu-Agyei S, Ansong D, Asante K, Kwarteng OS, Owusu R, et al. (2009) Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4: e7302.
39. Smith T, Hii J, Genton B, Muller I, Booth M, et al. (2001) Associations of peak shifts in age-prevalence for human malarias with bed net coverage. Trans R Soc Trop Med Hyg 95: 1-6.
40. Woolhouse ME, (1998) Patterns in parasite epidemiology: The peak shift. Parasitol Today 14: 428-434.
41. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, et al. (2011) Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 89: 821-830B.
42. da Silva A, Parent du Chatelet I, Beckr GA, Dompnier JP, Seck I, (2003) [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997]. Sante 13: 215-223.
43. Trape JF, Rogier C, (1996) Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 12: 236-240.
44. Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, et al. (2009) Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 27: 6203-6209.
45. GAVI Alliance (2011) Guidelines on Country Proposals.
46. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, et al. (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365: 1139-1146.
47. Levine OS, Knoll MD, Jones A, Walker DG, Risko N, et al. (2010) Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis 23: 236-241.